Highly Mutated COVID Variant BA.3.2 Spreads Across 25 US States

A New Viral Threat Emerges

A highly mutated COVID-19 variant with significant immune escape capabilities has now been confirmed across the United States and 22 other countries, raising concerns among health experts about potential vaccine effectiveness. The BA.3.2 variant, first identified in a respiratory sample in South Africa in November 2024, has roughly 70 to 75 substitutions and deletions in the gene sequence of its spike protein relative to the JN.1 variant and its descendant, LP.8.1, the antigens used in the latest COVID-19 vaccines.

BA.3.2 represents a new lineage of SARS-CoV-2, genetically distinct from the JN.1 lineages that have circulated in the United States since January 2024. The first U.S. BA.3.2 detection occurred on June 27, 2025, through CDC's Traveler-Based Genomic Surveillance program in a participant traveling to the United States from the Netherlands.

From November 2025 to January 2026, weekly BA.3.2 detections increased to about 30% of sequences in Denmark, Germany, and the Netherlands. The first US instance of BA.3.2 in a clinical specimen was documented on January 5, 2026. As of February 11, the strain's prevalence among 2,579 total genetic sequences in national surveillance collected starting on December 1, 2025, was 0.19%.

Widespread Detection Across America

The highly mutated SARS-CoV-2 BA.3.2 variant has been detected in nasal swabs collected from four US travelers, clinical samples from five patients, three airplane wastewater samples, and 132 wastewater surveillance samples from 25 states. This extensive detection pattern suggests the variant may already be circulating more widely than initial surveillance indicates.

"Because many countries have limited genomic detection and surveillance capacities, these detections likely underrepresent the actual geographic extent of spread," the researchers wrote. The wastewater surveillance data proves particularly telling, as it can detect viral presence in communities before clinical cases are formally identified.

On 5 December 2025, the WHO designated BA.3.2 as a variant under monitoring (VUM), citing the variant's many mutations and substantial antibody escape, and the variant's increasing growth in Western Australia. However, the WHO also believed that the variant did not yet demonstrate a sustained growth advantage over the other circulating SARS-CoV-2 variants, nor increased rates of deaths and hospitalizations.

Immune Escape Concerns

The most troubling aspect of BA.3.2 lies in its potential to evade existing immune protections. BA.3.2 is characterized by enhanced in vitro immune escape, with reduced neutralization from human serum antibodies induced by current COVID-19 vaccines. The 2025–2026 LP.8.1-adapted mRNA COVID-19 vaccine demonstrates protection against currently predominant JN.1 strains but had the lowest antibody neutralization against BA.3.2 in a laboratory study of seven variants, potentially affecting vaccine-conferred protection.

The observed increases in BA.3.2 detections, particularly in certain northern European countries, might be driven by substantial antibody evasion enabling infection of previously immune persons among populations in which previous variants circulated. This suggests that people who have been vaccinated or previously infected may still be vulnerable to this new strain.

In sera from individuals with prior confirmed SARS-CoV-2 infection or COVID-19 vaccination, neutralizing antibody titres against BA.3.2 were markedly lower than those against circulating JN.1-descendent variants, with sera from pre-Omicron cohorts reporting near complete loss of neutralizing activity.

What This Means Going Forward

Despite these concerning immune escape properties, current evidence suggests BA.3.2 may not represent an immediate crisis. In contrast to previous strain replacement events, BA.3.2 has not rapidly overtaken other variants; rather, in several European countries, BA.3.2 has cocirculated with various JN.1 descendant lineages with prevalences of approximately 10%–40%. BA.3.2 has not shown a sustained growth advantage over any other co-circulating variant, and no data indicate increased severity, hospitalisations, or deaths associated with this variant.

However, the variant's emergence highlights the ongoing evolution of SARS-CoV-2 and the need for continued vigilance. Health experts emphasize that more data is needed to determine the variant's transmissibility, severity, and immune escape potential. However, they say the findings may warrant updates to vaccine formulations if the strain continues to spread.

The detection of BA.3.2 across multiple states and countries underscores the importance of maintaining robust genomic surveillance systems and being prepared to adapt public health responses as new variants emerge. While this variant may not cause more severe illness, its ability to evade immunity could lead to increased transmission and breakthrough infections, particularly in vulnerable populations who rely on vaccines and previous infections for protection.